Abstract
Background and aim: Hepatitis C-related end stage liver disease (HCV-ESLD) is the leading primary indication for liver transplantation (LT). Recurrent HCV infection after LT is universal and most patients show manifested graft hepatitis. Accurate diagnosis is important in acute rejection in HCV-infected patients, as increased immunosuppression accelerates HCV-induced liver damage and shortens graft and patient survival. Aim of our study was to investigate the safety and the clinical value of this procedure in a large academic referral European LT center.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
